Cell-free Protein Synthesis Market

The cell-free protein synthesis market is projected to reach USD 308.9 million by 2030, growing from USD 217.2 million in 2025, with a CAGR of 7.3%. This growth is driven by the rising need to efficiently produce toxic and challenging proteins, the integration of AI/ML technologies, and increased adoption of reconstituted CFPS systems. Growth drivers include expanded applications in research, biopharmaceutical manufacturing, and diagnostics, as well as advances in high-throughput, automation, and scalable platforms. These innovations enhance the reliability, affordability, and versatility of cell-free systems for complex protein production. The market also offers promising opportunities in commercial validation, vaccine development, synthetic biology, biosensor creation, and expanding into personalized medicine and therapeutic proteins. Adoption among research labs and pharmaceutical firms is rising, thanks to CFPS's flexibility and rapid protein synthesis without live cells, which supports quick prototyping and faster R&D cycles.

To know about the assumptions considered for the study download the pdf brochure

New England Biolabs (UK)

New England Biolabs (NEB) is a leading company in the cell-free protein synthesis (CFPS) market, recognized for PURExpress reconstituted E. coli translation systems and complementary toolsets (T7 RNA polymerase, ribonuclease inhibitors, NTPs, DNA/RNA cleanup kits) that enable users to produce functional proteins from DNA templates within hours. NEB’s CFPS range includes standard, ΔRF123/Δaa variants for incorporation studies, and additional mixes for challenging targets, giving researchers precise control over initiation/termination, chaperone use, and labeling chemistries. Because NEB manufactures core enzymes in-house under strict quality control ensuring consistent lot-to-lot quality, labs can scale screens from microliter to milliliter volumes with minimal re-optimization—beneficial for academic labs, CROs, and biotech teams involved in rapid prototyping, enzyme engineering, toxic protein expression, or educational kits. The company’s extensive technical support, detailed protocols, and wide distribution network reduce time-to-result and procurement hurdles, while its consumables-focused approach (kits, enzymes, nucleotides) encourages recurring revenue and positions NEB as a trusted, cost-effective partner across CFPS workflows from template preparation to expression, detection, and downstream analysis.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a leading company in the cell-free protein synthesis market, offering a diverse range of bacterial, mammalian, and human cell lysate systems to meet various research needs. This variety allows the company to cater to different applications, from high-yield protein production with E. coli lysates to complex mammalian protein synthesis that requires native post-translational modifications. By providing specialized systems like the MembraneMax Protein Expression System for membrane proteins and the 1-Step Human Coupled IVT Kit for functional human proteins, Thermo Fisher offers flexibility that few competitors can match. This diversity boosts its market position by enabling Thermo Fisher to serve multiple customer segments, including academic researchers, CROs, and biopharmaceutical developers, each with unique expression needs. Additionally, its integration of protocol tools, optimized vectors, and targeted reagents improves experimental efficiency, helping to shorten development timelines and reduce costs for users. Supported by a global supply chain and strong technical support, Thermo Fisher’s portfolio not only generates ongoing revenue from consumables but also establishes the company as a trusted partner for innovation in protein synthesis workflows.

Promega Corporation (US)

Promega is a leading force in the cell-free protein synthesis (CFPS) market, providing a wide range of systems and reagents that address various protein expression needs. Its TNT Quick Coupled Transcription/Translation Systems and related platforms allow for fast, high-quality protein production directly from DNA or RNA templates, without the use of living cells. Promega’s portfolio includes both prokaryotic and eukaryotic cell-free expression systems, such as rabbit reticulocyte lysates, wheat germ extracts, and E. coli S30 systems, enabling researchers to choose the best platform for their specific protein. This variety supports applications like high-throughput functional screening, proteomics, structural biology, and the expression of proteins that are unstable, toxic, or membrane-bound. The company also offers various accessory reagents, including specialized expression vectors, control templates, amino acid mixtures, and protease inhibitors, which increase flexibility and improve experimental efficiency.

Market Ranking

The cell-free protein synthesis market is competitive, with no single company dominating the market. Thermo Fisher Scientific and Promega Corporation are recognized as global leaders, offering comprehensive CFPS portfolios that support in vitro transcription/translation, high-throughput proteomics, functional protein analysis, and synthetic biology workflows. Their diverse offerings, including bacterial, mammalian, and human cell-free systems, allow researchers to meet a wide range of protein expression needs. NEB is also known for its high-quality reagents and ongoing innovation, making it a trusted partner in academia and biotech. Thermo Fisher enhances its position through integrated CFPS solutions, extensive reagent libraries, and global distribution, while Promega emphasizes versatile coupled transcription/translation systems and specialized lysate platforms. QIAGEN distinguishes itself through GMP-compliant manufacturing and collaborations that incorporate CFPS into diagnostic workflows, boosting reliability for clinical applications. Smaller players such as CellFree Sciences, Sino Biological, Jena Bioscience GmbH, and niche CFPS providers constitute the remaining market share, often focusing on specialized systems for human cell lysate expression, high-yield synthesis, or unique protein modifications. As demand increases for rapid, flexible, and scalable protein synthesis in synthetic biology, drug discovery, protein engineering, and vaccine development, the market is poised for ongoing diversification and innovation.

Related Reports:

Cell-free Protein Synthesis Market by Offering (Cell Extract Systems (Prokaryotic, Mammalian, Plant), Kits, Instruments, Services), Workflow, Method (Coupled TX/TL, Transcription, Translation), Application (Protein Purification) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com